

Rising Cardiovascular Disease: A Key Driver Transforming the Urokinase Market 2024

The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only!

LONDON, GREATER LONDON, UNITED KINGDOM, December 17, 2024 /EINPresswire.com/ -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!



<u>In recent years, the urokinase market size has grown robustly</u>. Experts project a rise from \$1.61 billion in 2023 to \$1.70 billion in 2024, reflecting a compound annual growth rate CAGR of 5.7%.



The urokinase market size is expected to see strong growth in the next few years. It will grow to \$2.14 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%"

The Business Research
Company

Much of this buoyant performance during the historical period can be attributed to factors such as the increasing incidence of stroke and heart attacks, regulatory approvals for critical indications, as well as advancements in clinical research and a strengthening healthcare infrastructure. International focus on personalized medicine, the escalating prevalence of pulmonary embolism, and an uptick in cardiovascular and stroke research investment catalyse the market even further.

Dive Into Detailed Insights of the Global Urokinase Market with a Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19745&type=smp

Anticipated growth in the urokinase market size for the next few years is robust. By 2028, experts project an increase to \$2.14 billion, marking a compound annual growth rate CAGR of 5.8%. A key factor driving this growth is the increasing burden of cardiovascular diseases CVDs. CVDs, which include conditions such as heart attacks, strokes, and hypertension, are largely driven by rising obesity rates, poor dietary habits, and an aging global population.

The use of urokinase in preventing heart attacks and strokes by breaking down blood clots, restoring proper circulation, and mitigating further cardiovascular damage will become increasingly crucial. As per a 2022 report by the American College of Cardiology, alarming increases in rates for all four major cardiovascular risk factors are likely from 2025 to 2060, with diabetes expected to rise the most significantly 39.3% to 55 million individuals. The corresponding growth in the urokinase market is thus somewhat inevitable.

Pre-book the report for a swift delivery: https://www.thebusinessresearchcompany.com/report/urokinase-global-market-report

The urokinase market boasts a diverse collection of key industry players including Thermo Fisher Scientific Inc., Mochida Pharmaceutical Co. Ltd., Bharat Serums and Vaccines Limited, and Taj Pharmaceuticals Ltd., among others. These players, alongside others like Health Biotech Limited, Salvavidas Pharmaceutical Pvt. Ltd., and Aetos Pharma, are crucial in driving the market forward. An emerging trend amidst these industry bigwigs is the reintroduction and commercialization of pharmaceutical products for new uses — a strategy set to enhance market competitiveness, patient accessibility, and treatment efficacy.

The urokinase market is segmented in various ways:

- 1 By Type: Urokinase Powder, Urokinase Solution
- 2 By Manufacturing Process: Biotechnological Methods, Traditional Extraction
- 3 By Indication: Catheter Clearance, Coronary Artery Thrombosis, Deep Vein Thrombosis, Pulmonary Embolism
- 4 By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- 5 By Application: Hospital, Clinics, Other Applications

In terms of geographical analysis, North America represents the largest market for urokinase. However, as per the report, Asia-Pacific is primed to be the fastest-growing region in the forecast period. The urokinase market spans regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Tyrosine Kinase Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Janus Kinase (JAK) Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/cyclin-dependent-kinase-cdk-4-or-6-inhibitor-drugs-global-market-report

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

More about The Business Research Company can be found here, or contact us as follows:

The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company/ YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/768535050

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.